2
Mar
2020
Reconceiving the Value of Curative Therapies
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
27
Feb
2020
Gilead, Moderna Rise to the Occasion, Esperion Goes Back-to-Back, & Sangamo’s Big Neurology Deal
This week’s Frontpoints is a compilation of two weeks of deals, financings, and personnel moves. Coronavirus Thoughts If we learn one big lesson from this public health crisis, it should be that we need to continue to invest in our public agencies dedicated to science and public health – CDC, NIH and FDA, for starters. We also need to continue... Read More
24
Feb
2020
Facing Up to a Political Crisis: BIO Chairman Jeremy Levin on The Long Run
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
24
Feb
2020
Dissecting Biotech’s Living and Walking Dead
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
18
Feb
2020
Techlash Offers Health And Tech Opportunity To Reset Relationship, Rediscover Mutual Respect
Technology companies are experiencing a staggering reversal of reputational (though not financial) fortune; their stature seems reduced with each successive news cycle. Gone is the halo many tech companies once enjoyed. The implicit (and often explicit) assumption that tech innovation inevitably makes the world a better place has been replaced by real concerns that the picture may be far more... Read More
17
Feb
2020
As Scientists, It’s Our Duty to Speak Up as the 2020 Election Nears
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
13
Feb
2020
Lilly, Genentech Alzheimer’s Drugs Fail, Revolution’s Big IPO, & an Obesity Drug Disappears
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
12
Feb
2020
Automation and Miniaturization Are Upon Us: Gritstone’s Mission to Make Personalized Medicines
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
11
Feb
2020
The Cell Therapy Puzzle: Jane Grogan on The Long Run
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
Feb
2020
Sanofi’s Intriguing MS Drug, Merck’s Big Spinoff & Coronavirus Fog
Lots of shiny blinking objects are out there to pay attention to, but this was a week when a lot of fundamental hard work got done in biotech. Read about it in Frontpoints. Deal of the Week Merck is spinning off women’s health, biosimilars, and “trusted legacy brands” into a new company. The unnamed NewCo rolls together products expected to... Read More
6
Feb
2020
CAR-T for Autoimmunity: Bluestone Joins Sonoma Biotherapeutics, a $40M Bet
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
5
Feb
2020
First Buy, Then Invest: Novartis, Gilead Join $35M Bet on Vineti’s Software
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
30
Jan
2020
Coronavirus Fear Spreads, CVS Feels the Heat & Black Diamond’s Sizzling IPO
Last week, I was dismissive of the coronavirus outbreak stories. The internet was teeming with what struck me as alarmism. I’m still not running for the hills. I’m still rolling my eyes at the speed and volume of misinformation about coronavirus on the web. But more facts have since emerged to make this a more urgent and serious situation. We... Read More
27
Jan
2020
Scientists at the Movies: Relay Therapeutics CEO Sanjiv Patel on The Long Run
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
26
Jan
2020
Challenging Core Assumptions, Tech Backlash Paves The Way for More Thoughtful HealthTech
Digital transformation (as I recently discussed), and the implementation of emerging technologies more generally, is routinely pitched by enthusiasts like Tom Siebel as both urgent and inevitable, something organizations need to embrace or risk irrelevance, if not extinction. Yet the “embrace or die” assertion is under increasing, and healthy, scrutiny, as the “techlash” (technology backlash) gains steam. “Surveillance Capitalism”: Tech... Read More
23
Jan
2020
Incrementalism is the new Disruption, Trust is the New Black, and Positive Change (for now) at FDA: Takeaways from the 2020 Precision Medicine World Conference
I had the privilege of serving as emcee for the “Data Science and AI” track on the first day of this week’s Precision Medicine World Conference (PMWC) in Santa Clara, CA, as well as chairing a panel discussion on data mining and visualization. I came away with a sense of optimism and need, organized around several key themes. In Praise... Read More
23
Jan
2020
Much Ado About Coronavirus and 23andMe Hits the Wall
This was a quiet week in biopharma. Review it in your weekly Frontpoints. This Week in Alarmism Every year, we hear about an infectious disease scare that generates massive coverage, way out of proportion with the actual threat posed. Remember Mad Cow disease, SARS, Bird flu, Ebola, etc. etc? I’ve been in newsrooms providing saturation coverage of such things, and... Read More
22
Jan
2020
False Heroes: Pharmacy Benefit Managers and the Patients They Prey On
[Editor’s Note: this is an excerpt from “The Great American Drug Deal.” The book is now available on Amazon.] By Peter Kolchinsky It’s hard to know when actual prices for a particular drug really do go up, because there is so little transparency in pricing. A lot of the public discourse on pricing is based on “list prices,” which no... Read More
21
Jan
2020
Seeking to Understand Dr. King’s Vision of Unity, at Our Divided Moment
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
16
Jan
2020
Understanding The Ideology Of Digital Transformation
The phrase resounding in corporations these days is “digital transformation.” What does that really mean? According to proponents, digital transformation reflects the assertion that in order to remain competitive in the modern era, organizations need to radically rethink their approach to how they collect, manage, and analyze information. Change is clearly afoot, but the ideology informing this hasn’t been entirely... Read More